Projected Target Price for FYC Analyst: $104
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2025
0mins
Source: NASDAQ.COM
ETF Target Price Analysis: The First Trust Small Cap Growth AlphaDEX Fund ETF (FYC) has an implied analyst target price of $104.03 per unit, indicating a potential upside of 14.43% from its current trading price of $90.91.
Notable Holdings with Upside: Key underlying holdings such as Privia Health Group Inc (PRVA), Huron Consulting Group Inc (HURN), and Arcutis Biotherapeutics Inc (ARQT) show significant upside potential based on analyst target prices, with expected increases of 20.70%, 16.18%, and 15.13% respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRVA
Wall Street analysts forecast PRVA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.640
Low
23.00
Averages
30.40
High
34.00
Current: 22.640
Low
23.00
Averages
30.40
High
34.00
About PRVA
Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
Privia Health CFO Sells $283,000 Worth of Shares to Cover Taxes
- Transaction Overview: David Mountcastle, CFO of Privia Health Group, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000, indicating a liquidity move to cover tax obligations.
- Ownership Impact: This sale reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares and a mere 0.18% stake in the company, which may raise concerns about management stability among investors.
- Financial Context: Despite a 10.15% decline in PRVA's stock price in 2026, the company reported strong Q4 FY 2025 earnings, posting 7 cents per share, exceeding the 4-cent estimate, showcasing financial resilience.
- Market Reaction Advice: As the share sale was strictly for tax withholding related to the vesting of performance stock units, investors should not interpret this transaction negatively, especially given the company's acquisition of 1.5 million customers through an Accountable Care Organization, indicating potential for future growth.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
Privia Health CFO Sells $283,000 Worth of Shares to Cover Taxes
- Transaction Overview: David Mountcastle, CFO of Privia Health Group, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000, indicating a liquidity move to cover tax obligations.
- Ownership Impact: This sale reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares and a mere 0.18% stake in the company, which may raise concerns about management stability among investors.
- Financial Context: Despite a 10.15% decline in PRVA's stock price in 2026, the company reported strong Q4 FY 2025 earnings, posting 7 cents per share, exceeding the 4-cent estimate, showcasing financial resilience.
- Market Reaction Advice: As the share sale was strictly for tax withholding related to the vesting of performance stock units, investors should not interpret this transaction negatively, especially given the company's acquisition of 1.5 million customers through an Accountable Care Organization, indicating potential for future growth.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
